共 7 条
[1]
Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Enz A,Boddeke H,Gray J,et al. Annals of the New York Academy of Sciences . 1991
[2]
Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer’s disease. Sramek JJ,Anand R,Wardle TS,et al. Life Sciences . 1996
[3]
Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Polinsky RJ. Clinical Therapeutics . 1998
[4]
Rivastigmine .areviewofitsuseinAlzheimer’’sdisease. SpencerCM,NobleS. Drugs and Aging . 1998
[5]
Pharmacology and clinical efficacy of cholinesterase inhibitors. Jann MW. American Journal of Health System Pharmacy . 1998
[6]
Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Jann MW. Pharmacotherapy . 2000
[7]
Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease. Enz A,Amstutz R,Boddeke H,et al. Progress in Brain Research . 1993